// App-Quantinova.ai

AB0838 : IDENTIFYING MEDIATORS OF PAIN REDUCTION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH TOFACITINIB: ROLE OF INFLAMMATION ASSOCIATED WITH PERIPHERAL ARTHRITIS, ENTHESITIS AND SKIN DISEASE

Researchers

Presenter

  • P. C. Taylor

Principal Investigators

  • K. De Vlam

  • A. G. Bushmakin

  • L. Fallon

  • J. F. Merola

  • J. C. Cappelleri

  • M. A. Hsu

  • P. J. Mease

Medical Centers

  • University of Oxford, Oxford, United Kingdom

  • KU Leuven, Leuven, Belgium

  • Pfizer, Inc, Groton, CT, United States of America

  • Pfizer Canada, Montreal, QC, Canada

  • Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, United States of America

  • University of Washington, Washington, United States of America

Locations

  • United Kingdom

  • Belgium

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Spondyloarthritis

  • Psoriasis

Biomarkers

  • C reactive protein

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved